NCT04681144View on ClinicalTrials.gov

A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety

CompletedOBSERVATIONAL
Enrollment

103

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

November 21, 2022

Study Completion Date

November 21, 2022

Conditions
Prostate Cancer
Interventions
DRUG

Radium-223-dichloride (Xofigo, BAY88-8223)

Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04681144 - A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety | Biotech Hunter | Biotech Hunter